Better Buy Right Now: American Express vs. Bank of America

American Express reported Q1 revenue up 11% and EPS up 18% year over year, while Bank of America posted revenue growth of 7%, EPS growth of 25%, and a 9% jump in net interest income. Bank of America also raised its net interest income outlook to 6% to 8% growth and improved its efficiency ratio by 170 bps to 61%. The article is mostly comparative analysis, but it highlights both stocks as relatively cheap, with AXP at 18x forward earnings and BAC at 12x, and notes BAC has 81% buy-rated analysts versus 45% for AXP.

Analysis

The market is rewarding the cleaner earnings power: BAC is translating rate stickiness and better capital markets activity into visible near-term EPS momentum, while AXP is being punished for spending into growth even as its top-line remains intact. That creates a subtle but important divergence: BAC is more levered to cyclical beta and curve expectations, whereas AXP’s higher-quality affluent cardholder base should make its earnings profile less elastic in a slowdown. In other words, BAC is the better macro trade; AXP is the better business-quality trade.

The second-order effect the market may be missing is that BAC’s improving efficiency and credit metrics are a late-cycle green flag, but also a more fragile one if credit normalization stalls or funding costs re-accelerate. BAC’s valuation leaves less room for disappointment because the setup is already being re-rated on a quarter-to-quarter basis; any flattening in net interest income or softer loan growth can quickly compress multiple expansion. By contrast, AXP’s pullback looks more like a self-inflicted valuation reset from reinvestment spending than a deterioration in demand, which is usually the kind of dip that resolves over months rather than days.

Contrarianly, the consensus is probably underweighting how defensive AXP becomes if consumer stress rises: affluent spend tends to hold up longer, and its integrated network/issuer model lets it preserve economics better than pure lenders when credit tightens. BAC can still win on momentum, but the bar is now higher; AXP offers a better asymmetry if investors are willing to wait through one or two quarters of muted guidance. The key catalyst to watch is whether AXP’s reinvestment starts to show up in accelerated spend and card acquisition by mid-year; if not, the stock may stay range-bound despite cheapness.

Key Decisions for Investors

• Go long AXP on weakness over the next 1-3 weeks; use the current drawdown as entry for a 3-6 month mean reversion trade. Risk/reward: modest near-term downside if spending remains elevated, but 15-20% upside if management proves reinvestment is driving durable growth.
• Use BAC as a tactical momentum long only on confirmation of upward revisions in NII or capital markets revenue; prefer a 1-2 quarter horizon. Risk/reward: 8-12% upside if rates stay supportive, but multiple compression risk is high if the macro tape softens.
• Pair trade: long AXP / short BAC for a 3-6 month horizon to express quality-over-cyclical-beta. This isolates balance-sheet defensiveness and affluent consumer resilience against BAC’s greater sensitivity to funding costs and credit normalization.
• If you want event-driven exposure, buy AXP call spreads into the next earnings window; the setup favors a rebound if the market realizes guidance conservatism is funding growth investment rather than signaling deceleration.
• Avoid chasing BAC after the recent run unless you have a rates view; the stock is more dependent on continued positive revision momentum than AXP, so the marginal buyer is paying for a lot of good news already.